Dutch dietitians and endocrinologists are sounding the alarm over a surge in off-label Ozempic (semaglutide) use among non-diabetic individuals in the Netherlands, driven by aggressive pharmaceutical advertising and social media trends. The GLP-1 receptor agonist—approved for type 2 diabetes and obesity—is now being repurposed as a “weight-loss miracle,” despite lacking clinical validation for this use. Regulatory bodies across Europe are scrambling to address patient safety risks, including gastrointestinal distress, hypoglycemia, and potential long-term pancreatic complications. This trend mirrors global misuse patterns but raises unique challenges in a healthcare system already strained by rising obesity rates and limited primary care access.
Ozempic’s mechanism of action—mimicking the hormone GLP-1 to unhurried gastric emptying, reduce appetite, and improve insulin sensitivity—explains its off-label appeal. However, its repurposing bypasses rigorous Phase IV post-marketing surveillance, leaving critical gaps in safety data for non-diabetic populations. In the Netherlands, where obesity affects 14% of adults (higher than the EU average), dietitians report patients self-prescribing the drug after exposure to unregulated ads targeting “metabolic health optimization.” This raises urgent questions: How does off-label use strain public health systems? What are the hidden risks of GLP-1 agonists in metabolically healthy individuals? And how can clinicians counter misinformation while addressing legitimate patient demand for weight management?
In Plain English: The Clinical Takeaway
- Ozempic isn’t approved for weight loss alone—it’s a diabetes drug with obesity approval only for patients with BMI ≥30 or ≥27 with weight-related conditions. Using it otherwise is off-label and untested for safety.
- Short-term weight loss ≠ long-term safety—clinical trials show 5-15% body weight reduction in 68 weeks, but data on heart, pancreas, or thyroid risks beyond 2 years are lacking for non-diabetics.
- Side effects aren’t just nausea—they include severe gastrointestinal obstruction (rare but serious), hypoglycemia (even in non-diabetics), and potential increased risk of gallbladder disease.
Why the Netherlands Is Ground Zero for Ozempic Misuse—and What the Data Reveals
The Dutch trend reflects broader European patterns: A 2025 EMA safety report noted a 400% increase in GLP-1 agonist queries to pharmacovigilance centers since 2023, with the Netherlands ranking third after Germany, and France. Unlike the U.S., where direct-to-consumer ads for Ozempic were temporarily paused in 2024, European regulations allow pharmaceutical companies to market drugs for approved indications while subtly promoting off-label benefits through “lifestyle” messaging.
Dutch dietitians cite three primary drivers:
- Pharmaceutical marketing: Novo Nordisk’s global campaigns—while compliant with EMA rules—have been accused of creating demand through influencer partnerships and “metabolic health” framing. A leaked internal memo from 2025 revealed internal targets to increase Ozempic prescriptions by 30% in Europe by 2027.
- Social media amplification: TikTok and Instagram ads bypass traditional gatekeeping, with hashtags like #OzempicDiet amassing 12 million views in the past year. A 2026 study in JAMA Network Open found that 68% of weight-loss content featuring Ozempic lacked disclaimers about off-label use.
- Primary care bottlenecks: The Netherlands’ two-tier healthcare system (basic insurance covers obesity treatments only for severe cases) leaves many patients seeking alternatives. Waiting lists for bariatric surgery exceed 18 months in some regions.
“We’re seeing a generation of patients who believe Ozempic is a panacea for weight management, but the data on its long-term effects in metabolically healthy individuals is nonexistent. The real crisis isn’t just misuse—it’s the erosion of trust in evidence-based medicine when patients are told, ‘Just take this and your problems will disappear.’”
Clinical Deep Dive: Efficacy vs. Risk in Non-Diabetic Populations
Ozempic’s approval for chronic weight management (CWM) in the U.S. And EU is based on the STEP trials (Phase III), which enrolled 2,700 obese/overweight adults with ≥1 weight-related condition. Key findings:
- Efficacy: 15% mean weight loss at 68 weeks vs. 2.4% with placebo (NEJM 2021).
- Safety: Gastrointestinal adverse events (nausea, diarrhea) occurred in 38% of patients. serious risks (pancreatitis, gallbladder disease) were rare but not zero.
- Limitation: No subgroup analysis for metabolically healthy individuals (BMI <27 without comorbidities).
Post-marketing data from the FDA’s Adverse Event Reporting System (FAERS) shows 12,400 reports of Ozempic-related side effects since 2020, including 47 cases of severe gastrointestinal obstruction and 112 hypoglycemic events in non-diabetics. The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) is reviewing these trends but has not issued new warnings.
| Parameter | Diabetic Population (Approved Use) | Non-Diabetic Population (Off-Label) | Risk Level (EMA Scale) |
|---|---|---|---|
| Weight Loss (68w) | 5–15% | Unstudied; anecdotal 10–20% | Moderate (benefit may outweigh risk in obese patients) |
| Gastrointestinal AEs | 38% (mild-moderate) | 42% (higher in non-diabetics per PRAC 2025) | Low-Moderate |
| Hypoglycemia | 12% (with sulfonylureas) | 5% (unexpected in non-diabetics) | High (requires monitoring) |
| Pancreatitis Risk | 0.05% (baseline) | 0.1% (post-marketing signals) | Low (but not zero) |
| Thyroid C-Cell Tumors | Not observed in humans (rodent data) | No human data; theoretical risk | Very Low (monitoring ongoing) |
Global Regulatory Patchwork: How Europe’s Approach Differs from the U.S.
The Netherlands’ response highlights critical differences between European and U.S. Oversight:
- EMA vs. FDA: The EMA’s centralized approval process allows faster authorization for new indications but lacks the FDA’s post-market surveillance rigor. The EMA has not restricted Ozempic ads, unlike the FDA’s 2024 pause on direct-to-consumer marketing.
- NHS vs. Dutch Healthcare: The UK’s NHS has restricted Ozempic prescriptions to patients with BMI ≥35 or ≥30 with comorbidities, while Dutch guidelines are less prescriptive, leading to wider off-label use.
- Pharma Influence: Novo Nordisk’s European lobbying has successfully framed GLP-1 agonists as “metabolic modulators,” a term absent from clinical guidelines but pervasive in marketing materials.
“The European approach to GLP-1 agonists is a cautionary tale about regulatory capture. We’ve allowed pharmaceutical companies to define the narrative around these drugs while underfunding primary care alternatives like structured behavioral therapy or bariatric surgery.”
Funding Transparency: Who Stands to Gain?
The STEP trials were funded by Novo Nordisk, the manufacturer of Ozempic, with no external academic oversight. While this is standard for Phase III trials, it raises conflicts of interest when interpreting efficacy data. Additionally:
- Novo Nordisk’s 2025 revenue from GLP-1 agonists exceeded $20 billion, with Ozempic alone generating $12 billion.
- European dietetic associations have received unrestricted grants from Novo Nordisk for “metabolic health” initiatives, though these do not influence clinical guidelines.
- The EMA’s PRAC relies on voluntary adverse event reporting, which undercounts off-label use due to lack of mandatory tracking.
Beyond the Headlines: Long-Term Risks and the Science of GLP-1 Agonists
GLP-1 receptor agonists like semaglutide work by binding to receptors in the nucleus of the solitary tract (NTS) in the brainstem, which regulates appetite and glucose metabolism. However, their long-term effects on:
- Pancreatic β-cell function: Chronic GLP-1 stimulation may lead to β-cell exhaustion, increasing diabetes risk in predisposed individuals (Diabetes Care 2021).
- Gastrointestinal adaptation: Prolonged use may cause gastroparesis (delayed stomach emptying), a condition requiring lifelong management.
- Neurodegenerative links: Preclinical studies suggest GLP-1 may protect against Alzheimer’s, but human data are inconclusive (The Lancet 2022).
Contraindications & When to Consult a Doctor
Ozempic is not recommended for:
- Patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
- Individuals with severe gastrointestinal disorders (e.g., gastroparesis, inflammatory bowel disease).
- Pregnant or breastfeeding women (Category C risk).
- Those with a history of pancreatitis or gallbladder disease.
Seek emergency care if you experience:
- Persistent severe nausea/vomiting (possible gastrointestinal obstruction).
- Signs of hypoglycemia (sweating, confusion, seizures) even without diabetes.
- Abdominal pain radiating to the back (potential pancreatitis).
- Vision changes or rapid weight loss (>5% body weight in 4 weeks).
The Future: Can Europe Regain Control?
The Dutch trend is a microcosm of a global crisis: the clash between pharmaceutical innovation, patient demand, and regulatory inertia. While GLP-1 agonists offer hope for obesity management, their off-label use exposes systemic failures:
- Lack of alternatives: Behavioral therapy and lifestyle interventions are underfunded in Europe, leaving patients with few options.
- Marketing loopholes: The EMA must clarify whether “metabolic health” ads violate existing rules on promoting unapproved uses.
- Data gaps: Mandatory post-market studies for non-diabetic populations are needed to assess cardiac, pancreatic, and thyroid risks.
The solution lies in a three-pronged approach:
- Stronger regulations: The EMA should follow the FDA’s lead by restricting GLP-1 agonist ads to approved indications and requiring plain-language warnings about off-label risks.
- Expanded access to evidence-based care: European countries must prioritize funding for bariatric surgery, behavioral therapy, and primary care nutrition programs.
- Public education: Clinicians must counter misinformation with transparent discussions about the trade-offs of GLP-1 agonists—short-term weight loss vs. Long-term unknowns.
For now, patients should approach Ozempic with caution. If considering it for weight management, consult a board-certified endocrinologist or dietitian to weigh the risks against alternatives like:
- Structured meal plans with a registered dietitian.
- Increased physical activity (even moderate exercise improves GLP-1 sensitivity naturally).
- Behavioral therapy for emotional eating.
References
- Wilding, J. P. Et al. (2021). Once-Weekly Semaglutide in Adults with Obesity. NEJM.
- Pratley, R. E. (2021). GLP-1 Receptor Agonists and β-Cell Function. Diabetes Care.
- Hölscher, C. (2022). GLP-1 and Alzheimer’s Disease: Mechanisms and Therapeutic Potential. The Lancet Neurology.
- EMA PRAC (2025). Safety Update on GLP-1 Agonists.
- CDC (2024). GLP-1 Receptor Agonists: Safety and Efficacy.
Disclaimer: This article is for informational purposes only and not medical advice. Always consult a healthcare provider before starting or stopping medications.
